Onconomics RGCC Test
Onconomics RGCC Test
What are Identified ?
CTCs (Circulating-Tumour-Cells), Drug Sensitivity, Epigenetic Analysis.
Test Results
21 days *
Test Type
Comprehensive Test
Test Frequency
As required for treatment planning
Sample Required
Blood sampleCancer Type
All type of CancersBlood Sample Qty
15-20 ml peripheral whole bloodSample Test Report
DESCRIPTION
ONCONOMICS TEST RGCC, provides a detailed report on how effective specific anti-cancer treatments (cytotoxic drugs, monoclonal antibodies, a small molecule that inhibitor specific targets (TKI, etc.) are targeting Tumour Cells.
Test also includes the report of the Genetic Profiling of individuals tumour related Genes at the epigenetic level to understand the nature of cancer disease.
The combination of epigenetic analysis and viability assay results will help the doctors to identify effective treatment plans for treating the cancer for Personalised Cancer Treatments.
Research Articles
- Circulating tumor cells: biology and clinical significance.
- Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis
- Detection of Circulating Tumor Cells in Patients with Breast, Prostate, Pancreatic, Colon and Melanoma Cancer: A Blinded Comparative Study Using Healthy Donors
- A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer
- Cancer Comprehensive Analysis in Gastric Carcinoma: Benefits and New Perspectives
- Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
- Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model.
- Comparison of the growth curves of cancer cells and cancer stem cells
- Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases.
- Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value
Chemo Drugs List
Resistance Factors
Tumour Related Genes
Monoclonal Antibodies (MAB's) LIST
Small Molecular Weight Molecules (SMW)
Chemo Drugs List
Alkylating Agents
- Cisplatin
- Carboplatin
- Cyclophosphamide
- Ifosfamide
- Dacarbazine
- Oxaliplatin
- Mitomycin
- Treosulfan
- Temozolomide
- Procarbazine
- BCNU
- ACNU
- CCNU
- Bleomycin
- Melphalan
- Trofosfamidee
- Estramustine
- Bendamustine
- Nedaplatin
- Chlorambucil
- Hydroxyurea
- Altretamine
Epothilones
- Ixabepilone
Inhibitors of Topoisomerase I
- CPT11
- Topotecan
- Gimatecan
Inhibitors of Topoisomerase II
- Doxorubicin
- Liposomal_doxorubicin
- Epirubicin
- Daunorubicin
- Dactinomycin
- Idarubicin
- Etoposide
- Mitoxandrone
- Amrubicin_hydrochloride
Nucleus Spindle Stabilizer I
- Paclitaxel
- Docetaxel
- Eribulin
- Abraxane
- Cabazitaxel
Nucleus Spindle Stabilizer II
- Vincristine
- Vinblastine
- Vinorelbine
Nucleoside Analogues
- 5FU
- MTX
- Gemcitabine
- Capecitabine
- Fudr
- UFT
- Raltitrexed
- Pemetrexed
- Cytarabine
- Fludarabine
Resistance Factors
- MDR 1
- MRP
- LRP
- GST
Tumour Related Genes
- H-TERT
- Bcr-abl
- c-erb-B2
- c-erb-B1
- MTor
- Ras-Raf-MEK-Erk
- Nm23
- KISS-1-r
- Bcl-2
- Histone-deacetylase-dipeptide
- CypB1
- EGF
- TGF-b
- RET
- 06-methyltransferase I
- ALK
- EML – 4 – ALK
- NPM – ALK
- CD 117 (c-Kit)
- IGF – r – 1
- IGF – r- 2
- NR3C4-A
- NR3C4-B
- HSP90
- HSP72
- HSP27
- CES1-2
- HDAC
- HAT ANG1
- ANG2
- PARP (1 to 17)
- BCL-2
- CDK4\CDK6
- DLL3
- C-MET
- DNA-demethylase
- DNA methyltransferase I
- Ribonucleoside reductase
- IkB(a,b,c)
- NFkB
- GARFT
- SHMT
- DHFR
- TS
- MMP
- 5-LOX
- COX2
- PDGF
- FGF
- VEGF
- P16
- P53
- Gamma GC
- TP
- NP
- UP
- DPD
- P27
- Pl80
- E2Fl
- CES1-2
- Estrogen-Receptor
- Progesterone-Receptor
- SS-r
- HSP90
- RRMl
- CXCR4
- CXCR12
- CXCL12
- Bax
- CD95(fas-r)
- JAK 1/2
- 67LR
- PTEN
- c-Jun
- c-Fos
- ERCCl
Monoclonal Antibodies (MAB's) LIST
- Alemtuzumab
- Atezolizumab
- Avelumab
- Bevacizumab
- Brentuximab vedotin
- Catumaxumab
- Cetuximab
- Gemtuzumab
- Ibritumomab(Zevalin)
- Ipilimumab
- Nivolumab
- Ofatumumab
- Panitumumab
- Pembrolizumab
- Pertuzumab
- Ramucirumab
- Rituximab
- Tositumomab(Bexxar)
- Transtuzumab
Small Molecular Weight Molecules (SMW)
- Erlotinib
- Regorafenib
- Goserelin
- Antiandrogen(goserelin)
- Leprolide
- Abiraterone
- Sorafenib
- Everolimus/Temsirolimus
- Sunitinib
- Fulvestrant
- Tamoxifen
- Anastrozol
- Exemestane
- Gefitinib)
- 5-azacytidine
- Pazopanib
- Octreotide
- Axitinib
- Vemurafenib
- Trabectedin
- Crizotinib
- Ruxolitinib
- Imatinib-mesylate
- Nilotinib
- Dasatinib
- Vorinostat
- Olaparib
- Semaxanib
- Lapatinib
- Vandetanib
- Tramentinib
- Dabrafenib
- Palbociclib
- Afatinib
- Niraparib
- Veliparib
- Ponatinib
- Osimertinib
- Nintedanib
- Ziv-Aflibercept